. Author manuscript; available in PMC: 2018 Oct 1.

Published in final edited form as: J Steroid Biochem Mol Biol. 2016 Sep 13;173:139–147. doi: 10.1016/j.jsbmb.2016.09.009

Table 1. Genes showing significant upregulation in the enhancement phase of AraC toxicity.

HL60	Fold Change (comparing to control)		Difference	P value
Symbol	HL60-AraC	HL60-AraC-D2/CA	Combo - AraC	Combo vs AraC
BCL2L11 (BIM)	2.020	5.229	3.210	0.031
BRAF	0.749	3.189	2.440	0.028
U937	Fold Change (comparing to control)		Difference	p-values
Symbol	U937-AraC	U937-AraC-D2/CA	Combo - AraC	Combo vs AraC
BRAF	0.985	1.791	0.806	0.013
BCL2L11 (BIM)	1.661	2.415	0.754	0.044
AML-Ex vivo	Fold Change (comparing to control)			p-values
Symbol	AML-ex vivo-AraC	AML-AraC-D2/CA	Combo - AraC	Combo vs AraC
BRAF	1.22	2.94	1.728	N/A
BCL2L11 (BIM)	1.58	2.73	1.146	N/A

The genes are listed in the order of decreasing magnitude of the difference between AraC-D2/CA (Combo) and AraC alone. For details of the procedure see Materials and Methods Section. The genes shown here had the highest scores (the increase in expression when D2/CA added after AraC exposure) out of the 80 genes in the Array